Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy

Jerry M. Bergstein, Sharon Andreoli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12-66 months (mean 37 months). The average length of follow-up was 52 months (range 12-127 months). Compared with pretreatment values, the frequency of hematuria (13/16 vs. 8/16, P<0.05) and the levels of serum albumin (2.66 ± 0.69 vs. 3.76 ± 0.39 g/dl, P < 0.001), creatinine clearance (97 ± 37 vs. 129 ± 26 ml/ min/1.73 m2, P<0.001), and proteinuria (5.2 ± 5.1 vs. 1.0 ± 0.8 g/day, P<0.001) were significantly improved after 3 months of therapy. Improvement has persisted through the end of the follow-up period. Repeat kidney biopsies showed a significant reduction in acute changes but an increase in chronic changes. Thirteen patients have been off therapy from 1 to 74 months (mean 20.8 months). Nine have a normal urinalysis, creatinine clearance, and protein excretion. The remainder have normal renal function but proteinuria ranging from 3.2 to 4.3 g/day. The data support the evidence of other investigators that corticosteroid therapy is beneficial in type I MPGN and suggest that initiation with pulse methylprednisolone may promote early stabilization of the disease.

Original languageEnglish
Pages (from-to)268-271
Number of pages4
JournalPediatric Nephrology
Volume9
Issue number3
DOIs
StatePublished - Jun 1995

Fingerprint

Membranoproliferative Glomerulonephritis
Methylprednisolone
Prednisone
Proteinuria
Creatinine
Kidney
Biopsy
Urinalysis
Hematuria
Serum Albumin
Adrenal Cortex Hormones
Therapeutics
Research Personnel
Proteins

Keywords

  • Corticosteroids
  • Membranoproliferative glomerulonephritis
  • Nephrotic syndrome
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. / Bergstein, Jerry M.; Andreoli, Sharon.

In: Pediatric Nephrology, Vol. 9, No. 3, 06.1995, p. 268-271.

Research output: Contribution to journalArticle

@article{b6e176820b784195a75de9372da94a3b,
title = "Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy",
abstract = "Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12-66 months (mean 37 months). The average length of follow-up was 52 months (range 12-127 months). Compared with pretreatment values, the frequency of hematuria (13/16 vs. 8/16, P<0.05) and the levels of serum albumin (2.66 ± 0.69 vs. 3.76 ± 0.39 g/dl, P < 0.001), creatinine clearance (97 ± 37 vs. 129 ± 26 ml/ min/1.73 m2, P<0.001), and proteinuria (5.2 ± 5.1 vs. 1.0 ± 0.8 g/day, P<0.001) were significantly improved after 3 months of therapy. Improvement has persisted through the end of the follow-up period. Repeat kidney biopsies showed a significant reduction in acute changes but an increase in chronic changes. Thirteen patients have been off therapy from 1 to 74 months (mean 20.8 months). Nine have a normal urinalysis, creatinine clearance, and protein excretion. The remainder have normal renal function but proteinuria ranging from 3.2 to 4.3 g/day. The data support the evidence of other investigators that corticosteroid therapy is beneficial in type I MPGN and suggest that initiation with pulse methylprednisolone may promote early stabilization of the disease.",
keywords = "Corticosteroids, Membranoproliferative glomerulonephritis, Nephrotic syndrome, Treatment",
author = "Bergstein, {Jerry M.} and Sharon Andreoli",
year = "1995",
month = "6",
doi = "10.1007/BF02254181",
language = "English",
volume = "9",
pages = "268--271",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy

AU - Bergstein, Jerry M.

AU - Andreoli, Sharon

PY - 1995/6

Y1 - 1995/6

N2 - Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12-66 months (mean 37 months). The average length of follow-up was 52 months (range 12-127 months). Compared with pretreatment values, the frequency of hematuria (13/16 vs. 8/16, P<0.05) and the levels of serum albumin (2.66 ± 0.69 vs. 3.76 ± 0.39 g/dl, P < 0.001), creatinine clearance (97 ± 37 vs. 129 ± 26 ml/ min/1.73 m2, P<0.001), and proteinuria (5.2 ± 5.1 vs. 1.0 ± 0.8 g/day, P<0.001) were significantly improved after 3 months of therapy. Improvement has persisted through the end of the follow-up period. Repeat kidney biopsies showed a significant reduction in acute changes but an increase in chronic changes. Thirteen patients have been off therapy from 1 to 74 months (mean 20.8 months). Nine have a normal urinalysis, creatinine clearance, and protein excretion. The remainder have normal renal function but proteinuria ranging from 3.2 to 4.3 g/day. The data support the evidence of other investigators that corticosteroid therapy is beneficial in type I MPGN and suggest that initiation with pulse methylprednisolone may promote early stabilization of the disease.

AB - Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12-66 months (mean 37 months). The average length of follow-up was 52 months (range 12-127 months). Compared with pretreatment values, the frequency of hematuria (13/16 vs. 8/16, P<0.05) and the levels of serum albumin (2.66 ± 0.69 vs. 3.76 ± 0.39 g/dl, P < 0.001), creatinine clearance (97 ± 37 vs. 129 ± 26 ml/ min/1.73 m2, P<0.001), and proteinuria (5.2 ± 5.1 vs. 1.0 ± 0.8 g/day, P<0.001) were significantly improved after 3 months of therapy. Improvement has persisted through the end of the follow-up period. Repeat kidney biopsies showed a significant reduction in acute changes but an increase in chronic changes. Thirteen patients have been off therapy from 1 to 74 months (mean 20.8 months). Nine have a normal urinalysis, creatinine clearance, and protein excretion. The remainder have normal renal function but proteinuria ranging from 3.2 to 4.3 g/day. The data support the evidence of other investigators that corticosteroid therapy is beneficial in type I MPGN and suggest that initiation with pulse methylprednisolone may promote early stabilization of the disease.

KW - Corticosteroids

KW - Membranoproliferative glomerulonephritis

KW - Nephrotic syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0029073846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029073846&partnerID=8YFLogxK

U2 - 10.1007/BF02254181

DO - 10.1007/BF02254181

M3 - Article

VL - 9

SP - 268

EP - 271

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -